esketamine - Articles and news items

FDA grants breakthrough therapy designation for depression drug

Industry news / 16 August 2016 / Janssen

Following succesful phase II trials, the FDA have granted a Breakthrough Therapy Designation for esketamine, an investigational antidepressant medication…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+